Skip to main content
← All Companies
Pathos AI logo

Pathos AI

AI Native
AI Classification
AI is foundational, and the product wouldn't exist without it.

Chicago biotech Pathos AI closes $62M Series C at $600M valuation for AI-driven cancer drug development

Total Funding

$365M

Founded

2020

Headquarters

Chicago, United States

Industry Vertical

Health & Biotech

Technology Segments

Drug DiscoveryPrecision MedicineGeneticsBiotechnology

About

Pathos AI is an artificial intelligence-driven biotechnology company specializing in oncology drug development. Leveraging large multimodal datasets and proprietary machine learning models, Pathos AI aims to identify promising drug targets and optimize clinical trial design to improve outcomes for cancer patients. The company integrates genomic, transcriptomic, and real-world clinical information to predict drug efficacy and accelerate the progression of novel therapies.

With leadership experienced in both AI and precision medicine, Pathos AI is positioned at the forefront of computational approaches for transformative cancer treatments.

Funding Rounds

1
DateRoundAmount
2025-05-15Series D$365M

Investors

0

Investor data not available

Subscribe to Monday AI Signal

Weekly pre-seed and seed AI deal intelligence with early trends.